Evaluation of the in vitro activity of daptomycin against 19 615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 4, 2007, Pages 459-465

  Pfaller, Michael A ^a   Sader, Helio S ^b,c   Jones, Ronald N ^b,d  

^a UNIVERSITY OF IOWA   (United States)

^b JMI LABORATORIES   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Daptomycin; Gram positive infections; Staphylococcus aureus; Susceptibility

Indexed keywords

DAPTOMYCIN; OXACILLIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CANADA; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS; GRAM POSITIVE COCCI; HOSPITAL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 33947698450     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.10.007     Document Type: Article

References (32)

1. Akins R.L., Haase M.R., and Levy E.N. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy 26 (2006) 694-698
2. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38 (2004) 1673-1681
3. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38 (2004) 994-1000
4. Cha R., Brown W.J., and Rybak M.J. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 47 (2003) 3960-3963
5. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp G.R., Brown W.J., Cardo D., and Fridkin S.K. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348 (2003) 1342-1347
6. CLSI. Clinical and Laboratory Standards Institute. M7-A7, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 7th ed. (2006), CLSI, Wayne, PA
7. CLSI. Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement (2006), CLSI, Wayne, PA
8. Cunha B.A., Eisenstein L.E., and Hamid N.S. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 35 (2006) 207-211
9. Fluit A.C., Schmitz F.J., Verhoef J., and Milatovic D. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob. Agents Chemother. 48 (2004) 1007-1011
10. Fluit A.C., Wielders C.L., Verhoef J., and Schmitz F.J. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European, SENTRY study. J. Clin. Microbiol. 39 (2001) 3727-3732
11. Fuchs P.C., Barry A.L., and Brown S.D. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49 (2002) 467-470
12. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
13. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1 (2001) 147-155
14. Jevitt L.A., Smith A.J., Williams P.P., Raney P.M., McGowan Jr. J.E., and Tenover F.C. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 9 (2003) 389-393
15. Johnson A.P. Antibiotic resistance among clinically important Gram-positive bacteria in the UK. J. Hosp. Infect. 40 (1998) 17-26
16. Johnson A.P., Mushtaq S., Warner M., and Livermore D.M. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents 24 (2004) 315-319
17. Johnson A.P., Tysall L., Stockdale M.V., Woodford N., Kaufmann M.E., Warner M., Livermore D.M., Asboth F., and Allerberger F.J. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 21 (2002) 751-754
18. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24 (2003) 121-134
19. Liu C., and Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47 (2003) 3040-3045
20. Package Insert. Cubicin (Daptomycin for Injection) (2006), Cubist Pharmaceuticals, Inc, Lexington MA. Available at http://www.cubicin.com/2006_full_pi.pdf Accessed on June 28, 2006
21. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44 (2000) 1062-1066
22. Sader H.S., Fritsche T.R., and Jones R.N. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn. Microbiol. Infect. Dis. 53 (2005) 329-332
23. Sader H.S., Fritsche T.R., Streit J.M., and Jones R.N. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. J. Chemother. 17 (2005) 477-483
24. Sader H.S., Fritsche T.R., and Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 2330-2336
25. Sader H.S., Streit J.M., Fritsche T.R., and Jones R.N. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn. Microbiol. Infect. Dis. 50 (2004) 201-204
26. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering Jr. R.C., and Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 1581-1585
27. Schouten M.A., Voss A., and Hoogkamp-Korstanje J.A. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group. Antimicrob. Agents Chemother. 43 (1999) 2542-2546
28. Segreti J.A., Crank C.W., and Finney M.S. Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26 (2006) 347-352
29. Steenbergen J.N., Alder J., Thorne G.M., and Tally F.P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55 (2005) 283-288
30. Streit J.M., Jones R.N., and Sader H.S. Daptomycin activity and spectrum: a worldwide sample of 6,737 clinical Gram-positive organisms. J. Antimicrob. Chemother. 53 (2004) 669-674
31. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.C., and Ferraro M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
32. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., and Robbins M. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51 (2003) 186-188